Corrigendum to “A dose‐ranging study to determine the efficacy and safety of 1, 2, and 4 mg of dienogest daily for endometriosis” [International Journal of Gynecology and Obstetrics 108 (2010) 21–25]
erratum
OA: closed
CC0
⤵ 3 in-corpus citations
AI-generated summary
This corrigendum clarifies that analyses were based on the full-analysis set, adjusting Fig. 2 for missing rAFS scores and detailing histologic findings for endometriosis in the 2-mg and 4-mg dienogest groups.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
The authors wish to clarify that analyses in the paper are based on the full-analysis set (FAS), excluding patients for whom data were unavailable. For the revised American Fertility Society (rAFS) score, data were unavailable in 9.5% of patients in the 2-mg group group at 24 weeks. The columns in Fig. 2 are adjusted to 100%, after excluding these missing data. Histologic examination at 24 weeks in the 2-mg and 4-mg groups identified endometriosis in 33.3% and 46.7%, and no endometriosis in 28.6% and 30.0% of women, with data unavailable in 38.1% and 23.3%, respectively.
My notes (saved in your browser only)
Condition tags
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cited by (2)
Cited by (2)
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- unpaywall
- last seen: 2026-09-16T06:28:21.314993+00:00
License: CC0
· commercial use OK